Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

KIO-301

Small molecule · developed by Kiora Pharmaceuticals

Phase 2 Most advanced trial
KPRX Developer
2 Registered trials

What is KIO-301?

KIO-301 is an ophthalmic intravitreal formulation of the quaternary ammonium chloride salt KIO-300-Cl, whose active compound is KIO-300, in sulfobutylether-β-cyclodextrin, sucrose and phosphate buffer. It is studied in inherited retinal diseases, including retinitis pigmentosa and choroideremia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Ophthalmology
Developer
Kiora Pharmaceuticals, Inc. (KPRX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
57HBP7XKS9

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06628947 Phase 2 Retinitis Pigmentosa Recruiting KPRX
NCT05282953 Phase 1/2 Retinitis Pigmentosa Completed KPRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

ChoroideremiaNon-Syndromic Rod-Dominant Inherited Retinal DiseasesRetinitis Pigmentosa

More from Kiora Pharmaceuticals

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the KPRX page.

Follow KPRX, the company behind KIO-301

See KPRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

KPRX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.